Targeted therapy in HER2-positive metastatic breast cancer: A review of the literature

Current Oncology

Volumn 22, Issue , 2015, Pages S19-S28

  Zhu, X ^a   Verma, S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

HER2; Metastatic breast cancer; Phase III trials; Targeted therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TYROSINE KINASE RECEPTOR;

ANEMIA; BLOOD BRAIN BARRIER; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE CONTROL; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERTUZUMAB; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 84940397123     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2363     Document Type: Review

References (41)

1. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto, ON: Canadian Cancer Society; 2013.
2. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the her-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-62.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The her-2 receptor and breast cancer: ten years of targeted anti-her-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
4. Citri A, Yarden Y. egf-ErbB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
5. Baselga J, Cortés J, Kim SB, et al. on behalf of the cleopatra study group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987;235:177-82.
7. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of her-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
8. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7.
9. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/ HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 2013;141:507-14.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
11. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase iii study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with her-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92.
12. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965-72.
13. Andersson M, Lidbrink E, Bjerre K, et al. Phase iii randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the hernata study. J Clin Oncol 2011;29:264-71.
14. Valero V, Forbes J, Pegram MD, et al. Multicenter phase iii randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (bcirg 007 study): two highly active therapeutic regimens. J Clin Oncol 2011;29:149-56.
15. Gelmon KA, Boyle F, Bella K, et al. Open-label phase iii randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (l) or trastuzumab (t) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (ia) of ncic ctg ma.31/gsk egf 108919 [abstract LBA671]. Presented at the 2012 asco Annual Meeting. [Available online at: http://meetinglibrary.asco.org/ content/102986-114; cited October 21, 2014]
16. Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 2013;31:1947-53.
17. Swain SM, Kim S, Cortés J, et al. Final overall survival (os) analysis from the cleopatra study of first-line (1L) pertuzumab (Ptz), trastuzumab (t), and docetaxel (d) in patients (pts) with HER2-positive metastatic breast cancer (mbc) [abstract 350O_PR]. Presented at the 2014 Annual Congress of the European Society for Medical Oncology. [Accessible online at: https://www.webges.com/cslide/library/esmo/browse/ itinerary/478/2014-09-28#9f9n02vU (look for the title at Presidential Symposium 1, and click the Abstract tab); cited October 12, 2014]
18. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
19. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase iii tandem study. J Clin Oncol 2009;27:5529-37.
20. Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer-results of the electra trial. Breast 2012;21:27-33.
21. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. [Erratum in: N Engl J Med 2007;356:1487]
22. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
23. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
24. Verma S, Miles D, Gianni L, et al. on behalf of the emilia study group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91. [Erratum in: N Engl J Med 2013;368:2442]
25. André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (bolero-3): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet Oncol 2014;15:580-91.
26. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012;30:2585-92.
27. Wang L, Zhang Q, Zhang J, et al. pi3k pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011;11:248.
28. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with her-2-positive advanced breast cancer: final survival analysis of a phase iii randomized trial. Oncologist 2010;15:924-34.
29. Giordano SH, Temin S, Kirshner JJ, et al. on behalf of the American Society of Clinical Oncology. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2078-99.
30. Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-63.
31. Pestalozzi BC, Zahrieh D, Price KN, et al. on behalf of the International Breast Cancer Study Group. Identifying breast cancer patients at risk for Central Nervous System (cns) metastases in trials of the International Breast Cancer Study Group (ibcsg). Ann Oncol 2006;17:935-44.
32. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86.
33. Cameron D, Casey M, Press M, et al. A phase iii randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
34. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (landscape): a single-group phase 2 study. Lancet Oncol 2013;14:64-71.
35. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2100-8.
36. Baselga J, Cortes J, Im SA, et al. Biomarker analyses in cleopatra: a phase iii, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014;32:3753-61.
37. Baselga J, Verma S, Ro J, et al. Relationship between tumor biomarkers (bm) and efficacy in emilia, a phase iii study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (mbc) [abstract LB-63]. Presented at the 2013 Annual Meeting of the American Association for Cancer Research; Washington, DC, U.S.A.; April 6-10, 2013. [Available online at: http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey=1e9ae007-6c50-46e2-951f-4b825865e743&cKey=15187a93-e3d3-443c-81b5-24d4f5e7bf0d; cited November 14, 2014]
38. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248-62.
39. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.
40. Dokter W, Ubink R, van der Lee M, et al. Preclinical profile of the HER2-targeting adc SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther 2014;13:2618-29.
41. Verheijden G, Beusker P, Ubink R, et al. Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (adc) [abstract 626]. J Clin Oncol 2014;32(suppl):. [Available online at: http://meetinglibrary.asco.org/ content/131605-144; cited November 11, 2014]